Z-2460-2026 Class II Ongoing

Recalled by Accriva Diagnostics, Inc. — San Diego, CA

FDA device recall Z-2460-2026 was initiated by Accriva Diagnostics, Inc. on Apr 30, 2026 and is designated Class II. Reason for recall: Assayed Whole blood control contains labeling with incorrect performance range. The recall status is ongoing. Affected quantity: 6060.

Recall details

Product Type
Devices
Report Date
Jun 24, 2026
Initiation Date
Apr 30, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
6060

Product description

directCHECK ACT-LR whole blood quality control, level 2 Model/Catalog Number: DCGLR-2

Reason for recall

Assayed Whole blood control contains labeling with incorrect performance range.

Distribution pattern

Worldwide - US Nationwide distribution including in the states of AL, AR, AZ, CA, FL, GA, ID, IL, IN, KY, MA, MD, MI, MN, MO, MT, NC, NJ, NM, NY, OH, OK, PA, SC, TN, TX, VA, VT, WA, WI, WV and the countries of Canada, Hong Kong, Spain.

Code information

Lot #: A6DLA001 Unique Device Identifier: 10711234170373

Source

Dataset
openFDA device recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for Z-2460-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for Z-2460-2026. Report a data issue: hello@regdatalab.com.